Dynamic Medium Voltage Therapy Control for Muscle Fatigue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medium voltage therapy (MVT) techniques are limited in duration due to muscle fatigue, failing to provide effective cardiac perfusion for extended periods during cardiac arrhythmias such as pulseless electrical activity (PEA) and asystole, as conventional devices lack dynamic adjustment and targeted muscle stimulation.
Innovation Solution
Advanced monitoring and control systems in implantable and external devices dynamically adjust MVT parameters and target specific muscles based on patient conditions, using waveform characteristics and location-specific electrode configurations to prolong treatment efficacy and reduce muscle fatigue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If medium voltage therapy is applied continuously to maintain cardiac perfusion during cardiac arrhythmias, then cardiac output and perfusion are improved, but muscle fatigue develops limiting the duration of effective therapy
Solution Approach 1:
The patent segments the MVT delivery by alternating between different muscle groups (e.g., left ventricle, right ventricle, skeletal muscles) in a cyclic manner. This allows one muscle group to be stimulated while another rests, preventing fatigue accumulation and enabling prolonged therapy duration without compromising perfusion effectiveness.
Solution Approach 2:
The patent implements periodic action by cycling through different stimulation patterns and muscle groups at defined intervals. The system alternates between MVT delivery to cardiac muscles and skeletal muscles, and includes rest periods between cycles, creating a periodic stimulation pattern that prevents continuous fatigue while maintaining hemodynamic support.
2Stress or pressure
If high intensity MVT is applied to force cardiac output during arrest, then perfusion pressure is improved, but energy consumption increases and muscle fatigue accelerates
Solution Approach 1:
The patent applies local quality by delivering MVT to specific muscle groups (cardiac vs. skeletal muscles) based on the immediate hemodynamic needs. The system can target the left ventricle for forward flow, right ventricle for pulmonary circulation, or skeletal muscles for mechanical compression, optimizing energy use by stimulating only the most effective muscle group for the current physiological state.
Solution Approach 2:
The patent changes MVT parameters (amplitude, duration, frequency) dynamically based on the detected arrhythmia type and hemodynamic response. The system adjusts stimulation intensity and pattern to achieve adequate perfusion pressure while minimizing energy consumption and avoiding excessive muscle fatigue.
3Productivity
If MVT is applied to stimulate both cardiac and skeletal muscles, then hemodynamic effect is improved, but device complexity increases
Solution Approach 1:
The patent implements universality by designing the MVT system to deliver stimulation through common electrodes for both cardiac muscles and skeletal muscles. The same device and electrode configuration can stimulate the left ventricle, right ventricle, and skeletal muscle groups by simply changing the stimulation pattern and timing, eliminating the need for separate dedicated electrode sets for each muscle type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables longer duration and more effective MVT sessions, improving cardiac perfusion and increasing the chances of successful defibrillation or spontaneous circulation return by adaptively varying intensity and targeting muscle groups to manage fatigue and optimize hemodynamic effects.
Implementation Method 1
electrodes are used to administer MVT and to make the measurement
Data Source
AI summary
Aspects of the invention are directed to advanced monitoring and control of medium voltage therapy (MVT) in implantable and external devices. Apparatus and methods are disclosed that facilitate dynamic adjustment of MVT parameter values in response to new and changing circumstances such as the patient's condition before, during, and after administration of MVT. Administration of MVT is automatically and dynamically adjusted to achieve specific treatment or life-support objectives, such as prolongation of the body's ability to endure and respond to MVT, specifically addressing the type of arrhythmia or other pathologic state of the patient with targeted treatment, a tiered-intensity MVT treatment strategy, and supporting patients in non life-critical conditions where the heart may nevertheless benefit from a certain level of assistance.